The Challenges of Preventive Screenings
Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some item...
Ausführliche Beschreibung
Autor*in: |
Stephanie Holmquist [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2014 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Voices in Bioethics - Columbia University Libraries, 2020, 1(2014) |
---|---|
Übergeordnetes Werk: |
volume:1 ; year:2014 |
Links: |
---|
DOI / URN: |
10.7916/vib.v1i.6542 |
---|
Katalog-ID: |
DOAJ022635408 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ022635408 | ||
003 | DE-627 | ||
005 | 20230307060501.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2014 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.7916/vib.v1i.6542 |2 doi | |
035 | |a (DE-627)DOAJ022635408 | ||
035 | |a (DE-599)DOAJad3cd6e49c0d482297a5ad6d99b82c3a | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a R723-726 | |
050 | 0 | |a BJ1-1725 | |
100 | 0 | |a Stephanie Holmquist |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Challenges of Preventive Screenings |
264 | 1 | |c 2014 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014). | ||
650 | 4 | |a preventive care | |
650 | 4 | |a preventive screenings | |
650 | 4 | |a genetic testing | |
653 | 0 | |a Medical philosophy. Medical ethics | |
653 | 0 | |a Ethics | |
773 | 0 | 8 | |i In |t Voices in Bioethics |d Columbia University Libraries, 2020 |g 1(2014) |w (DE-627)1741547725 |x 26914875 |7 nnns |
773 | 1 | 8 | |g volume:1 |g year:2014 |
856 | 4 | 0 | |u https://doi.org/10.7916/vib.v1i.6542 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/ad3cd6e49c0d482297a5ad6d99b82c3a |z kostenfrei |
856 | 4 | 0 | |u https://journals.library.columbia.edu/index.php/bioethics/article/view/6542 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2691-4875 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2086 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 1 |j 2014 |
author_variant |
s h sh |
---|---|
matchkey_str |
article:26914875:2014----::hcalneopeetv |
hierarchy_sort_str |
2014 |
callnumber-subject-code |
R |
publishDate |
2014 |
allfields |
10.7916/vib.v1i.6542 doi (DE-627)DOAJ022635408 (DE-599)DOAJad3cd6e49c0d482297a5ad6d99b82c3a DE-627 ger DE-627 rakwb eng R723-726 BJ1-1725 Stephanie Holmquist verfasserin aut The Challenges of Preventive Screenings 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014). preventive care preventive screenings genetic testing Medical philosophy. Medical ethics Ethics In Voices in Bioethics Columbia University Libraries, 2020 1(2014) (DE-627)1741547725 26914875 nnns volume:1 year:2014 https://doi.org/10.7916/vib.v1i.6542 kostenfrei https://doaj.org/article/ad3cd6e49c0d482297a5ad6d99b82c3a kostenfrei https://journals.library.columbia.edu/index.php/bioethics/article/view/6542 kostenfrei https://doaj.org/toc/2691-4875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2086 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2014 |
spelling |
10.7916/vib.v1i.6542 doi (DE-627)DOAJ022635408 (DE-599)DOAJad3cd6e49c0d482297a5ad6d99b82c3a DE-627 ger DE-627 rakwb eng R723-726 BJ1-1725 Stephanie Holmquist verfasserin aut The Challenges of Preventive Screenings 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014). preventive care preventive screenings genetic testing Medical philosophy. Medical ethics Ethics In Voices in Bioethics Columbia University Libraries, 2020 1(2014) (DE-627)1741547725 26914875 nnns volume:1 year:2014 https://doi.org/10.7916/vib.v1i.6542 kostenfrei https://doaj.org/article/ad3cd6e49c0d482297a5ad6d99b82c3a kostenfrei https://journals.library.columbia.edu/index.php/bioethics/article/view/6542 kostenfrei https://doaj.org/toc/2691-4875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2086 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2014 |
allfields_unstemmed |
10.7916/vib.v1i.6542 doi (DE-627)DOAJ022635408 (DE-599)DOAJad3cd6e49c0d482297a5ad6d99b82c3a DE-627 ger DE-627 rakwb eng R723-726 BJ1-1725 Stephanie Holmquist verfasserin aut The Challenges of Preventive Screenings 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014). preventive care preventive screenings genetic testing Medical philosophy. Medical ethics Ethics In Voices in Bioethics Columbia University Libraries, 2020 1(2014) (DE-627)1741547725 26914875 nnns volume:1 year:2014 https://doi.org/10.7916/vib.v1i.6542 kostenfrei https://doaj.org/article/ad3cd6e49c0d482297a5ad6d99b82c3a kostenfrei https://journals.library.columbia.edu/index.php/bioethics/article/view/6542 kostenfrei https://doaj.org/toc/2691-4875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2086 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2014 |
allfieldsGer |
10.7916/vib.v1i.6542 doi (DE-627)DOAJ022635408 (DE-599)DOAJad3cd6e49c0d482297a5ad6d99b82c3a DE-627 ger DE-627 rakwb eng R723-726 BJ1-1725 Stephanie Holmquist verfasserin aut The Challenges of Preventive Screenings 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014). preventive care preventive screenings genetic testing Medical philosophy. Medical ethics Ethics In Voices in Bioethics Columbia University Libraries, 2020 1(2014) (DE-627)1741547725 26914875 nnns volume:1 year:2014 https://doi.org/10.7916/vib.v1i.6542 kostenfrei https://doaj.org/article/ad3cd6e49c0d482297a5ad6d99b82c3a kostenfrei https://journals.library.columbia.edu/index.php/bioethics/article/view/6542 kostenfrei https://doaj.org/toc/2691-4875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2086 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2014 |
allfieldsSound |
10.7916/vib.v1i.6542 doi (DE-627)DOAJ022635408 (DE-599)DOAJad3cd6e49c0d482297a5ad6d99b82c3a DE-627 ger DE-627 rakwb eng R723-726 BJ1-1725 Stephanie Holmquist verfasserin aut The Challenges of Preventive Screenings 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014). preventive care preventive screenings genetic testing Medical philosophy. Medical ethics Ethics In Voices in Bioethics Columbia University Libraries, 2020 1(2014) (DE-627)1741547725 26914875 nnns volume:1 year:2014 https://doi.org/10.7916/vib.v1i.6542 kostenfrei https://doaj.org/article/ad3cd6e49c0d482297a5ad6d99b82c3a kostenfrei https://journals.library.columbia.edu/index.php/bioethics/article/view/6542 kostenfrei https://doaj.org/toc/2691-4875 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2086 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2014 |
language |
English |
source |
In Voices in Bioethics 1(2014) volume:1 year:2014 |
sourceStr |
In Voices in Bioethics 1(2014) volume:1 year:2014 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
preventive care preventive screenings genetic testing Medical philosophy. Medical ethics Ethics |
isfreeaccess_bool |
true |
container_title |
Voices in Bioethics |
authorswithroles_txt_mv |
Stephanie Holmquist @@aut@@ |
publishDateDaySort_date |
2014-01-01T00:00:00Z |
hierarchy_top_id |
1741547725 |
id |
DOAJ022635408 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ022635408</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307060501.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.7916/vib.v1i.6542</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ022635408</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJad3cd6e49c0d482297a5ad6d99b82c3a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R723-726</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">BJ1-1725</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Stephanie Holmquist</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Challenges of Preventive Screenings</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014).</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">preventive care</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">preventive screenings</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">genetic testing</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical philosophy. Medical ethics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ethics</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Voices in Bioethics</subfield><subfield code="d">Columbia University Libraries, 2020</subfield><subfield code="g">1(2014)</subfield><subfield code="w">(DE-627)1741547725</subfield><subfield code="x">26914875</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2014</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.7916/vib.v1i.6542</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ad3cd6e49c0d482297a5ad6d99b82c3a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://journals.library.columbia.edu/index.php/bioethics/article/view/6542</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2691-4875</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2014</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Stephanie Holmquist |
spellingShingle |
Stephanie Holmquist misc R723-726 misc BJ1-1725 misc preventive care misc preventive screenings misc genetic testing misc Medical philosophy. Medical ethics misc Ethics The Challenges of Preventive Screenings |
authorStr |
Stephanie Holmquist |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1741547725 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
R723-726 |
illustrated |
Not Illustrated |
issn |
26914875 |
topic_title |
R723-726 BJ1-1725 The Challenges of Preventive Screenings preventive care preventive screenings genetic testing |
topic |
misc R723-726 misc BJ1-1725 misc preventive care misc preventive screenings misc genetic testing misc Medical philosophy. Medical ethics misc Ethics |
topic_unstemmed |
misc R723-726 misc BJ1-1725 misc preventive care misc preventive screenings misc genetic testing misc Medical philosophy. Medical ethics misc Ethics |
topic_browse |
misc R723-726 misc BJ1-1725 misc preventive care misc preventive screenings misc genetic testing misc Medical philosophy. Medical ethics misc Ethics |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Voices in Bioethics |
hierarchy_parent_id |
1741547725 |
hierarchy_top_title |
Voices in Bioethics |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1741547725 |
title |
The Challenges of Preventive Screenings |
ctrlnum |
(DE-627)DOAJ022635408 (DE-599)DOAJad3cd6e49c0d482297a5ad6d99b82c3a |
title_full |
The Challenges of Preventive Screenings |
author_sort |
Stephanie Holmquist |
journal |
Voices in Bioethics |
journalStr |
Voices in Bioethics |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2014 |
contenttype_str_mv |
txt |
author_browse |
Stephanie Holmquist |
container_volume |
1 |
class |
R723-726 BJ1-1725 |
format_se |
Elektronische Aufsätze |
author-letter |
Stephanie Holmquist |
doi_str_mv |
10.7916/vib.v1i.6542 |
title_sort |
challenges of preventive screenings |
callnumber |
R723-726 |
title_auth |
The Challenges of Preventive Screenings |
abstract |
Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014). |
abstractGer |
Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014). |
abstract_unstemmed |
Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014). |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2086 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
title_short |
The Challenges of Preventive Screenings |
url |
https://doi.org/10.7916/vib.v1i.6542 https://doaj.org/article/ad3cd6e49c0d482297a5ad6d99b82c3a https://journals.library.columbia.edu/index.php/bioethics/article/view/6542 https://doaj.org/toc/2691-4875 |
remote_bool |
true |
ppnlink |
1741547725 |
callnumber-subject |
R - General Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.7916/vib.v1i.6542 |
callnumber-a |
R723-726 |
up_date |
2024-07-04T02:16:30.833Z |
_version_ |
1803612995805249536 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ022635408</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307060501.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.7916/vib.v1i.6542</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ022635408</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJad3cd6e49c0d482297a5ad6d99b82c3a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R723-726</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">BJ1-1725</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Stephanie Holmquist</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Challenges of Preventive Screenings</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Implementing preventive care and screening test strategies to reduce disease and illness continues to prove challenging. Assessing the efficacy of screening and preventive interventions requires ongoing monitoring and consistent revision of standards of care to incorporate new information. Some items recently in the news echo the continuing difficulties of crafting preventive strategies to deliver real benefits. Preventive care ought to reduce the incidence of disease. However, prevention efforts may pose unanticipated risks. Reporting in the current issue of Infection Control and Hospital Epidemiology, U.S. investigators asked, “Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits?” 1 The answer appears to be yes. While the goal of well child visits is health maintenance, this study’s authors identified pediatric waiting rooms as a potent source of infection for children and their parents. Based in data from 1998-2006, conservative estimates are that wellness visits may be responsible for as many as 700,000 excess cases of influenza in the U.S. each year. The authors suggest two strategies for reducing the numbers of incidental flu infections from well child visits—adherence to standard infection control policies in waiting rooms and scheduling well-child visits outside of peak influenza seasons. When and if mammography’s benefits outweigh the risks of over-diagnosis and treatment of breast cancer continues to be in dispute. Publishing in the February 11th issues of the British Medical Journal, Canadian researchers concluded that screening women under 60 produces no benefit when compared to breast self-exam plus an annual physician exam. The authors are reporting further findings of a contentious study, now in its 25th year.2 This Canadian research adds to uncertainties for women and their physicians. In 2009, the independent U. S. Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward. As in breast cancer, over-diagnosis and treatment of non-aggressive prostate cancers diminishes quality of life. Faced with elevated PSA scores, physicians and patients have had few tools to guide decisions on opting for “watchful waiting” or choosing surgical and other interventions—and their risks. New research suggests genetic assessment of the risk of aggressive prostate cancer may be available soon for improved clinical guidance. Reporting in the British Journal of Cancer on February 20th, researchers identified 13 mutations predisposing their carriers to invasive forms of prostate cancer. 5 Among the genes tested for were variants of BRCA1 and BRCA2, familiar as risk factors in some heritable breast cancers. Genetic testing combined with PSA screening should allow for more accurate risk assessment timely treatment for some men at higher risk. References and Further Reading 1 Simmering, J. E. Are Well-Child Visits a Risk Factor for Subsequent Influenza-Like Illness Visits? Infection control and hospital epidemiology 35, 251-256, doi:10.1086/675281 (2014). 2 Miller, A. B. et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, doi:10.1136/bmj.g366 (2014). 3 Force, U. S. P. S. T. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine 151, 716-726, W-236, doi:10.7326/0003-4819-151-10-200911170-00008 (2009). 4 Woolf, S. H. THe 2009 breast cancer screening recommendations of the us preventive services task force. JAMA 303, 162-163, doi:10.1001/jama.2009.1989 (2010). 5 Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer, doi:10.1038/bjc.2014.30 (2014).</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">preventive care</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">preventive screenings</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">genetic testing</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical philosophy. Medical ethics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ethics</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Voices in Bioethics</subfield><subfield code="d">Columbia University Libraries, 2020</subfield><subfield code="g">1(2014)</subfield><subfield code="w">(DE-627)1741547725</subfield><subfield code="x">26914875</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2014</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.7916/vib.v1i.6542</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ad3cd6e49c0d482297a5ad6d99b82c3a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://journals.library.columbia.edu/index.php/bioethics/article/view/6542</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2691-4875</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2014</subfield></datafield></record></collection>
|
score |
7.400714 |